Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

Freenome announced improved validation data for its updated SimpleScreen CRC blood-based colorectal cancer screening test, demonstrating 18.2% sensitivity for advanced precancerous lesions (up from 13.7%) and 80.4% sensitivity for colorectal cancer detection at 90% specificity. The FDA-approved test, commercialized by partner Abbott Cancer Diagnostics, will be presented at ACG 2026 Annual Meeting in Nashville.